A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders

Clinical Cancer Research

Volumn 15, Issue 19, 2009, Pages 6217-6224

  Duvic, Madeleine ^a   Reddy, Sunil A ^b   Pinter Brown, Lauren ^d   Korman, Neil J ^e   Zic, John ^f   Kennedy, Dana A ^g   Lorenz, Jennie ^g   Sievers, Eric L ^g   Kim, Youn H ^c  

^a University of Texas Health Science Center at Houston   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c STANFORD CANCER INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^f VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^g SEATTLE GENETICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SGN 30;

ACUTE HEART INFARCTION; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACKACHE; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG SAFETY; FATIGUE; FEMALE; FOLLOW UP; HUMAN; HYPOKALEMIA; INSOMNIA; LARGE CELL LYMPHOMA; LYMPHOMATOID PAPULOSIS; MALE; MULTICENTER STUDY; MYCOSIS FUNGOIDES; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; SKIN INFECTION; TREATMENT RESPONSE;

ADULT; AGED; ALGORITHMS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOTHERAPY; LYMPHOMA, LARGE-CELL, ANAPLASTIC; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 70349662167     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0162     Document Type: Article

References (23)

1. + cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. J AmAcad Dermatol 2003;49:1049-1058
2. + cutaneous lymphoproliferative disorders: a clinicopathologic study of 65 cases. AmJ Surg Pathol 1998;22:1192-1202
3. Bekkenk MW, Geelen FA, van Voorst Vader PC, et al. Primary and secondary cutaneous CD30 (+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-termf ollow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 2000;95:3653-3661
4. Kadin ME, Carpenter C. Systemic and primary cutaneous anaplastic large cell lymphomas. Semin Hematol 2003;40:244-256 (Pubitemid 36842602)
5. + diseases: anaplastic large-cell lymphoma and lymphomatoid papulosis. Cancer Treat Res 2008;142:349-365
6. Vergier B, de Muret A, Beylot-Barry M, et al. French Study Group of Cutaneious Lymphomas. Transformation of mycosis fungoides: clinico-pathological and prognostic features of 45 cases. Blood 2000;95:2212-2218
7. Nakahigashi K, Ishida Y, Matsum ura Y, et al. Large cell transformation mimicking regional lymphomatoid papulosis in a patient with mycosis fungoides. J Dermatol 2008;35:283-288 (Pubitemid 351678095)
8. + lympho-proliferative disorders. J Invest Dermatol 2009; 129:89-98.
9. Perna AG, Jones DM, Duvic M. Lymphomatoid papulosis fromchildhood with anaplastic large-cell lymphoma of the small bowel. Clin Lymphoma 2004;5:190-193 (Pubitemid 40227711)
10. Talpur R, Jones DM, Alencar AJ, et al. CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma. J Invest Dermatol 2006;126:575-583 (Pubitemid 43255644)
11. Duvic M. Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies. Oncology (Williston Park) 2007;21:33-40.
12. + lymphoma. Haematologica 1995;80:357-366
13. Younes A, Carbone A. CD30/CD30 ligand and CD40/CD40 ligand in malignant lymphoid disorders. Int J Biol Markers 1999;14:135-143 (Pubitemid 29495742)
14. Chiarle R, Podda A, Prolla G, Gong J, Thorbecke GJ, Inghirami G. CD30 in normal and neoplastic cells. Clin Immunol 1999;90:157-164
15. Gardner LJ, Polski JM, Evans HL, Perkins SL, Dunphy CH. CD30 expression in follicular lymphoma. Arch Pathol Lab Med 2001;125:1036-1041
16. Horie R, Watanabe T. CD30: expression and function in health and disease. Semin Immunol 1998;10:457-470 (Pubitemid 28564375)
17. Wahl AF, Klussman K, Thompson JD, et al. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res 2002;62:3736-3742 (Pubitemid 34728855)
18. + hematologic malignancies [abstract]. Blood 2002;100:362-3a.
19. Fairclough DL, Cella DF. Functional Assessment of Cancer Therapy (FACT-G): non-response to individual questions. Qual Life Res 1996;5:321-329
20. Cella DF. Manual of the functional assessment of chronic illness therapy (FACIT) scales (version 4). Evanston (IL): Northwestern University; 1997.
21. Cvetkovic RS, Perry CM. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2006;66:791-820.
22. Blick SK, Scott LJ. Cetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer. Drugs 2007;67:2585-2607 (Pubitemid 350159168)
23. Vonderheid EC, Sajjadian A, Kadin ME. Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30- positive lymphoproliferative disorders. J Am Acad Dermatol 1996;34:470-481 (Pubitemid 26083827)